This week\u2019s headlines include, recent survey shows doctors likely slow to prescribe biosimilar mAbs, pediatricians support embryonic Stem Cell Research, new cartilage stem cell study, flu vaccine has other health benefits, biotech business developments, and new information on mumps vaccine.\n\nCell Culture Events:\n\nAttend Cell Culture World Congress USA, November 12th and 13th in Washington, D.C.\nTaking place in Washington, D.C. on November 12th and 13th, Cell Culture World Congress USA is the conference for biopharma and biotechs seeking to optimize cell culture development. This event brings together leading biopharma and biotechs to discuss recent advancements in upstream and downstream cell-culture processes \u2013 advancements that will help improve bio-processing efficiency, optimize R&D, reduce production time and minimize costs.\n\nFor more information download our brochure at www.terrapinn.com\/CCdishBro.\n\nIf you are interested in registering, you can do so at www.terrapinn.com\/CCdishReg.\n\nEnter the promo code CCD to save 15% off your registration fee!\n\nHeadlines:\n\n\u201cHealth Companies Sitting on Cash May Mean Bigger Deals,\u201d Bloomberg\n\nHealth-care companies sitting on piles of cash may start doing more deals next year as they seek products that can bolster sales, said four top U.S. dealmakers.\u00a0 Pharmaceutical companies in particular, which have led the industry in deals over the last 12 months, are ready to divert their focus from cutting costs to making agreements that can help build product lines, said Jennifer Jarrett, managing director of investment banking at Citigroup Inc.\n\nIf you like this story, please see our blog titled \u201cVenture Capital Investment in the Life Science Sector is Down for 2012 \u2013 Is There a Light at the End of the Tunnel\u201d\n\n \n\n\u201cSurvey: Many Docs Will Be Slow to Switch to Biosimilar mAbs,\u201d Fierce Biotech\n\nA large majority of oncologists around the world seem eager to switch their patients to biosimilar versions of ESA and G-CSF therapies once they become readily available, according to a new survey out from BioTrends Research Group. But there was a distinct hesitancy noted in the U.S. when the conversation turned to the first generation of biosimilars for the monoclonal antibodies like rituximab (Roche's $5.6 billion drug MabThera).\n\nIf you like this story, please see our blog titled \u201cComments on Biosimilar Guidance Indicate Discontent on Both Sides of the Issues\u201d\n\n \n\n\u201cPediatricians OK Embryonic Stem Cell Research,\u201d Med Page Today\n\nCiting its potential for use in pediatric diseases, the American Academy of Pediatrics has thrown its support behind human embryonic Stem Cell Research. The research has possible implications for certain childhood diseases, including hypoxic-ischemic encephalopathy, bone marrow failure syndromes, leukemia, congenital heart disease, neonatal lung disease, and type 1 diabetes, according to members of the academy's committees on pediatric research and bioethics. And significant progress has already been made in basic and translational research using human embryonic stem cells, they wrote in a policy statement published online ahead of the November issue of Pediatrics.\n\nIf you like this story, please see our blog titled \u201cHow Stem Cells Can Play a Major Role in Developing New Therapeutics\u201d\n\n \n\n\u201cThe 2012 Biotech Graveyard,\u201d Fierce Biotech\n\nIn Fierce Biotech\u2019s fourth installment of their "Graveyard Report" of company failures, they report that biotech's boneyard has seen relatively little activity over the past year.\u00a0 Fewer biotech outfits closed their doors this year than all previous years of the Graveyard report.\n\nIf you like this story, please see our blog titled \u201cFDA Strives to Provide Faster Approval Time for Drugs by Employing \u201cSpecial Medical Use\u201d Category\u201d\n\n \n\n\u201cStem Cells to Cartilage? Promising Results Seen in Mice,\u201d US News and World Report Health Day\n\nScientists who created cartilage from adult stem cells in mice say their success could lead to new treatments for cartilage injury and osteoarthritis. The cartilage was created using induced pluripotent stem cells, which are adult cells that have been genetically altered to have the characteristics of embryonic stem cells. Induced pluripotent stem cells (iPSCs) have the potential to become different types of specialized cells. "What this research shows in a mouse model is the ability to create an unlimited supply of stem cells that can turn into any type of tissue -- in this case cartilage, which has no ability to regenerate by itself," study senior author Farshid Guilak, a professor of orthopedic surgery at Duke University in Durham, N.C., said in a university news release.\n\nIf you like this story, please see our blog titled \u201cCultureware \u2013 A New Generation of Products Step Up to the Plate\u201d\n\n\u201cMumps Outbreak Traced to Face-to-Face Schooling,\u201d Reuters\n\nA face-to-face educational technique used among Orthodox Jews apparently led to an outbreak of mumps in 2009 and 2010 even though most of those infected were properly vaccinated, according to a new study. The outbreak, detailed in the November 1 New England Journal of Medicine, illustrates how close repeated contact with an infected person can overwhelm the mumps vaccine. "The risk of infection with mumps may be higher when the exposure dose of virus is large or intensely transmitted," the researchers concluded in their report. This may also explain why the mumps vaccine tends to be less effective among household contacts than among school or community contacts, they added.\n\nIf you like this story, please see our blog titled \u201cLean Development Approaches in the Era of Quality by Design \u2013 Mission Impossible?\n\n \n\n\u201cFlu Vaccine May Protect Your Heart,\u201d US News and World Report Health Day\n\nGetting a flu shot may help people stay healthy in more than the obvious way, new research suggests. "The shot doesn't just protect you against flu, it protects you from heart attacks," said Dr. Jacob Udell, a cardiologist at Women's College Hospital and the University of Toronto. In his research, Udell found that those who got a flu shot reduced their risk of heart attacks and other serious cardiovascular problems by nearly half during a one-year follow-up period.\n\nIf you like this story, please see our blog titled \u201cManufacturing Strategies for Improving Viral Yield and Lowering Production Cost in Vaccine Manufacturing\u201d\n\n \n\n\nCreate your free online surveys with SurveyMonkey, the world's leading questionnaire tool.